Karyopharm Therapeutics Inc. announced last week that it raised $48.2 million in a Series B financing, a rather large round these days, especially for a Series B. Read More
Drugs continue to fail. Most candidates that enter into the development process do not come out the other end as approved therapies. But the reasons for those failures have shifted. Read More
